ABLEDOCS
6.4.2021 14:03:02 CEST | Business Wire | Pressemeddelelse
AbleDocs Inc. , globalt førende udbyder af tilgængelige PDF-produkter og -services, og Diversa Docs ApS , anerkendte eksperter inden for PDF- og Web-tilgængelighedsydelser, annoncerer, at de går sammen for at blive førende i Skandinavien inden for PDF-tilgængelighedsprodukter og -services.
Med en allerede mangeårig historik for samarbejde glæder begge virksomheders grundlæggere og lederteam til at udnytte hinandens muligheder for at tilbyde større fordele til eksisterende og nye kunder.
”Diversa Docs er bredt anerkendt for deres ekspertise inden for levering af PDF/UA-kompatible og tilgængelige PDF-filer, og denne erhvervelse giver vores kombinerede kundebase mulighed for at drage fordel af oplevelsen og omfanget af vores produkter og tjenester i hele Skandinavien,” siger AbleDocs 'Præsident (GLOBAL), Adam Spencer .
”Med deres fantastiske hold og fokuserede tilgang på slutbrugeren er de den ideelle partner for AbleDocs. Med vores samlede indsats kan sammen vi drive udbredelsen af næste generations PDF-tilgængelighedstjenester og -løsninger, ”siger Vice President (SCANDINAVIA), Jens Bjerre Kirkegaard .
”Tilgængelighed har altid appelleret til mig, fordi det kombinerer et teknisk felt med et humanistisk område,” siger administrerende direktør for Diversa Docs, Asbjørn Fangel-Hansen . ”Efter at have arbejdet i 12 år i den danske offentlige sektor inden for tilgængelighed og senest som ejer af en af de førende virksomheder inden for tilgængelighed i Danmark, er jeg meget beæret over at blive en del af en af de absolut førende globale aktører, når det kommer til tilgængelige dokumenter, ”tilføjer Fangel-Hansen.
Kombinationen af AbleDocs og Diversa Docs vil udvide den globale tilstedeværelse af AbleDocs med produkter, services, udvikling af løsninger og uddannelse tilpasset til lokale forhold på 49 sprog for at sikre, at kunderne får de bedst mulige tilbud.
Om Diversa Docs
Diversa Docs ApS blev grundlagt af Lars Holm-Sørensen og Asbjørn Fangel-Hansen i 2019 som søsterselskab til Diversa ApS. Siden da har virksomheden udviklet sig til at være en af de førende i Danmark med hensyn til dokumenttilgængelighed og området generelt.
Om AbleDocs Inc.
AbleDocs blev grundlagt i 2019 som et konglomerat af udbydere af PDF-tilgængelighedstjenester og er vokset til at have aktiviteter i Canada, Danmark, Tyskland, Schweiz og USA. Grundlæggerne har mere end 150 års kombineret erfaring med tilgængelige dokumenter i og har siden udvidet sine tilbud til også at inkludere en helt ny tilgang til dokumenttilgængelighedsstrategier og løsninger til tilgængelige dokument produceret i store mængder samt test af tilgængelige dokumenter.
AbleDocs er det eneste firma i verden, der garanterer, at hver fil, de producerer, overholder gældende lovgivning for tilgængelighed og bakker det op med en garanti på $ 10.000.000.
Aktuelle produkter og services fra AbleDocs inkluderer ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord og axesPDF.
For mere information, besøg https://www.abledocs.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210406005231/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
